InnotiveDx Secures £1 Million Grant From PACE for UTI Diagnostic Innovation

InnotiveDx's Commitment to Combatting UTI and AMR

Innotive Diagnostics (InnotiveDx) is thrilled to announce that it has won a significant grant of £1 million from PACE (Pathways to Antimicrobial Clinical Efficacy). This funding will propel the development of its advanced diagnostic system specifically designed for rapidly detecting urinary tract infections (UTIs). The cornerstone of this initiative is the innovative InnotiveUTI test, which promises to deliver both bacterial identification and antimicrobial susceptibility testing results within an impressive timeframe of less than 60 minutes.

Every year, hundreds of millions of individuals worldwide suffer from UTIs, resulting in a staggering consumption of over 20% of all antibiotic prescriptions. This reality exacerbates the pressing issue of antimicrobial resistance (AMR), leading not only to unforeseen hospital admissions but also imposing enormous financial burdens on healthcare systems globally, amounting to billions of dollars. As the medical community increasingly recognizes the urgent need for efficient diagnostic solutions, InnotiveDx’s technology emerges as a pivotal component in addressing these challenges.

The team at InnotiveDx stands out for developing a UTI diagnostic solution that has proven extremely reliable—offering an accuracy exceeding 96% in blinded evaluations. The technology transitions smoothly into fully automated prototypes, reflecting the company’s commitment to setting new standards in diagnostic efficiency. With the backing of the £1 million PACE grant, InnotiveDx will be able to evaluate the performance of its prototypes across thousands of clinical specimens. Such thorough testing is essential before the technology is deployed for real-world clinical pilot studies.

James Mainwaring, the Chief Commercial and Operating Officer of InnotiveDx, expressed his enthusiasm regarding the funding, stating, “This grant is an enormous validation of our technology and the dedication our team has shown since the inception of our spin-off. Tackling AMR is among the most critical challenges we face today, and we are keen to collaborate with PACE and other companies to make a significant impact.”

Dr. Beverley Isherwood, Program Director at PACE, praised InnotiveDx's achievement, commenting, “Congratulations to Innotive Diagnostics! We are thrilled to welcome them into the PACE portfolio following a highly competitive funding call for diagnostics. We will work alongside InnotiveDx, supporting their endeavor to generate critical validation data, essential for further development, funding, and investment.”

InnotiveDx is a pioneering in-vitro diagnostics enterprise dedicated to introducing transformative diagnostic solutions. The InnotiveUTI test is a game-changer that aims to ensure accurate and prompt diagnoses of UTIs at the point of care — a stark contrast to existing methods, where timely diagnostic options are notably lacking.

Understanding the Role of PACE

PACT is one of the UK’s prominent public-private collaborations involving Innovate UK, LifeArc, and the Medicines Discovery Catapult. These organizations are fundamentally focused on accelerating antimicrobial drug discovery and development, thus addressing urgent medical needs in the global healthcare arena. Through strategic investments in pioneering projects like those from InnotiveDx, PACE seeks to elevate the standards in antimicrobial effectiveness and diagnostics.

As the world increasingly grapples with the issue of antimicrobial resistance, InnotiveDx stands ready to bring innovative solutions to the forefront, not only improving outcomes for patients but also assisting healthcare providers in their continued efforts toward responsible antibiotic stewardship. The future of UTI diagnostics is on the horizon with InnotiveDx leading the charge.